Amyloid PET burden (centiloids) in early symptomatic Alzheimer's disease patients treated with trontinemab, lecanemab or donanemab

Trontinemab resulted in rapid, dose-dependent brain amyloid burden reduction, with amyloid plaque cleared (centiloids < 24) by week 12 - it takes donanemab 52 weeks to do so.